Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment
Durani U, Manana A, May J, Nelson M, Zheng Z, Gollapudi A, Alam S, Reynolds R, Thompson J, Kumbamu A, Das D, Murphy M, Henry E, Lee A, Marshall A, Wun T, Weeks L. Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment. Blood 2020, 136: 20-21. PMCID: PMC8330314, DOI: 10.1182/blood-2020-143347.Peer-Reviewed Original ResearchMental health resourcesCOVID-19Health resourcesMental healthPrivate practiceImmune-compromised patientsLow patient volumeAmerican SocietyCOVID-19 pandemicPrevalence of burnoutMost respondentsPatient care responsibilitiesOverall cohortPercent of respondentsClinical careClinical OncologyPatient volumeNon-clinical workPrevalence variedMajority of traineesFellow experienceTrainee researchReduced motivationRespondent demographicsAdmission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
Goshua G, Liu Y, Meizlish M, Fine R, Amin K, Chang E, Liu Y, McManus D, Petrosan A, Chaar C, Chun H, Defilippo N, Neuberg D, Owusu K, Lee A. Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis. Blood 2020, 136: 23-24. PMCID: PMC8330288, DOI: 10.1182/blood-2020-143349.Peer-Reviewed Original ResearchIntermediate-dose anticoagulationAnti-platelet therapyAnticoagulation cohortOverall cohortMultivariable regression modelingRothman IndexDose anticoagulationHospital deathD-dimerPropensity scoreHospitalized patientsMechanical ventilationClinical trialsCOVID-19Prophylactic-dose anticoagulationRisk-stratified algorithmUse of aspirinChronic kidney diseasePropensity-Matched AnalysisEfficacy of aspirinSeverity of illnessAnti-platelet agentsMulti-site cohortImpact of aspirinSmall vessel thrombosis